Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry

• Status: Withdrawn
• Trial end date: 2020-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is a prospective observational study in which patients undergoing treatment for leishmaniasis with miltefosine (Impavido) in the US and who weigh > 75 kg can volunteer to provide information about their clinical response to treatment up to 6 months after the start of treatment.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Knight Therapeutics (USA) Inc
• Treatments: Miltefosine

Criteria

Inclusion Criteria:

1. Did the subject give consent to collect data from her or her physician?

2. Was the subject treated for leishmaniasis with miltefosine?

3. Does the subject weigh more than 75 kg?

Exclusion Criteria:

[none]